Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: The EPICAL study

This publication has 40 references indexed in Scilit:

• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
  New England Journal of Medicine, 1999
• Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?
  International Journal of Cardiology, 1997
• A Cardiologist's Perspective on Evolving Concepts in the Management of Congestive Heart Failure
  The Journal of Clinical Pharmacology, 1996
• Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])**See Appendix for full list of RALES investigators.
  The American Journal of Cardiology, 1996
• Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals
  The American Journal of Cardiology, 1996
• Current Guidelines for the Treatment of Congestive Heart Failure
  Drugs, 1996
• Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor
  The American Journal of Cardiology, 1993
• The Place of Angiotensin-Converting Enzyme Inhibition in the Treatment of Cardiovascular Diseases
  New England Journal of Medicine, 1988
• Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
  The American Journal of Cardiology, 1988
• Effects of Enalapril on Mortality in Severe Congestive Heart Failure
  New England Journal of Medicine, 1987